Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial

DOI record: { "DOI": "10.1101/2021.03.28.21254507", "URL": "http://dx.doi.org/10.1101/2021.03.28.21254507", "abstract": "<jats:title>Summary</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The proportion of critically ill COVID-19 patients has collapsed hospital care worldwide. The need for alternative therapies for this group of patients is imperative. This study aims to compare the safety and efficacy of convalescent plasma (CP) compared with human immunoglobulin (IVIg) in patients requiring the administration of high oxygen levels or mechanical ventilation.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This is a controlled, randomized, open clinical trial of patients with pneumonia secondary to SARS-CoV-2 infection, that fulfilled criteria for severe or critical disease. They were randomized in a 1:2 ratio; group 1 was administered IVIg at a dose of 0.3 grams per kilogram of ideal weight, in an 8-hour infusion every 24 hours, for 5 days. Group 2 was administered 200 ml of CP infused in 2 hours, for 2 days. The primary outcomes were duration of hospitalization and mortality at 28 days.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>One hundred and ninety (190) patients were randomized; 130 to the CP group, and 60 to the IVIg group. Their average age was 58 years (IQR 47 – 72), and most were male (n= 119, 62.6 %). On inclusion, 85.2 % of patients (n=162) were on invasive mechanical ventilation therapy. Overall mortality in all included patients was 53 % (n= 102), with a median follow-up of 14 days (IQI 8 – 26). Mortality at 28 days was 45.2 % (n=86). In the intention-to-treat analysis, there was no difference between groups neither in mortality on follow-up (53.8 vs. 53.3, p =1.0) nor at 28 days (46.2 vs 43 %, p=0.75, Log Rank p = 0.83). Per-protocol analysis between treatment groups revealed no difference in mortality throughout hospitalization (51.5 vs 51.4 %, p=1.0) nor after 28 days (42.1 vs 42.87 %, p=0.92 Log Rank p = 0.54). Only 23 patients in the CP group received plasma with detectable anti-SARS-CoV-2 antibodies.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In critically ill patients or on invasive mechanical ventilation for treatment of Covid-19, the use of CP is not superior to IVIg in terms of hospitalization duration or mortality. The use of CP is based on complex logistics and requires an assured level of antibodies if used therapeutically. IVIg does not appear to be useful in this group of patients.</jats:p><jats:p><jats:bold>clinicaltrials.gov identifier:<jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04381858\">NCT04381858</jats:ext-link></jats:bold>.</jats:p></jats:sec>", "accepted": { "date-parts": [ [ 2021, 3, 31 ] ] }, "author": [ { "affiliation": [], "family": "Gonzalez", "given": "Jose Lenin Beltran", "sequence": "first" }, { "affiliation": [], "family": "González Gámez", "given": "Mario", "sequence": "additional" }, { "affiliation": [], "family": "Mendoza Enciso", "given": "Emmanuel Antonio", "sequence": "additional" }, { "affiliation": [], "family": "Esparza Maldonado", "given": "Ramiro Josue", "sequence": "additional" }, { "affiliation": [], "family": "Palacios", "given": "Daniel Hernández", "sequence": "additional" }, { "affiliation": [], "family": "Campos", "given": "Samuel Dueñas", "sequence": "additional" }, { "affiliation": [], "family": "Robles", "given": "Itzel Ovalle", "sequence": "additional" }, { "affiliation": [], "family": "Macías Guzmán", "given": "Mariana Jocelyn", "sequence": "additional" }, { "affiliation": [], "family": "García Díaz", "given": "Andrea Lucia", "sequence": "additional" }, { "affiliation": [], "family": "Gutiérrez Peña", "given": "César Mauricio", "sequence": "additional" }, { "affiliation": [], "family": "Reza-Escalera", "given": "Ana Lilian", "sequence": "additional" }, { "affiliation": [], "family": "Tiscareño Gutierrez", "given": "Maria Teresa", "sequence": "additional" }, { "affiliation": [], "family": "Galvan-Guerra", "given": "Elva", "sequence": "additional" }, { "affiliation": [], "family": "Dorantes Morales", "given": "Maria del Rocio", "sequence": "additional" }, { "affiliation": [], "family": "Medina", "given": "Lucila Martínez", "sequence": "additional" }, { "affiliation": [], "family": "Monroy Colin", "given": "Victor Antonio", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-7430-702X", "affiliation": [], "authenticated-orcid": false, "family": "Jose Manuel", "given": "Arreola Guerra", "sequence": "additional" } ], "container-title": [], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2021, 3, 31 ] ], "date-time": "2021-03-31T16:55:10Z", "timestamp": 1617209710000 }, "deposited": { "date-parts": [ [ 2022, 12, 23 ] ], "date-time": "2022-12-23T01:30:32Z", "timestamp": 1671759032000 }, "group-title": "Infectious Diseases (except HIV/AIDS)", "indexed": { "date-parts": [ [ 2023, 1, 14 ] ], "date-time": "2023-01-14T10:51:34Z", "timestamp": 1673693494835 }, "institution": [ { "name": "medRxiv" } ], "is-referenced-by-count": 11, "issued": { "date-parts": [ [ 2021, 3, 31 ] ] }, "link": [ { "URL": "https://syndication.highwire.org/content/doi/10.1101/2021.03.28.21254507", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "246", "original-title": [], "posted": { "date-parts": [ [ 2021, 3, 31 ] ] }, "prefix": "10.1101", "published": { "date-parts": [ [ 2021, 3, 31 ] ] }, "publisher": "Cold Spring Harbor Laboratory", "reference": [ { "key": "2021040207250726000_2021.03.28.21254507v1.1", "unstructured": "World Health Organization. Coronavirus Disease (COVID-19). Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (Accessibility verified January 15, 2021)" }, { "key": "2021040207250726000_2021.03.28.21254507v1.2", "unstructured": "World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV. February 11, 2020. Available at: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. (Accessibility verified January 15, 2021)" }, { "DOI": "10.1001/jama.2020.24865", "doi-asserted-by": "crossref", "key": "2021040207250726000_2021.03.28.21254507v1.3", "unstructured": "Woolf SH , Chapman DA , Lee JH . COVID-19 as the leading cause of death in the United States. JAMA. 2021; 325:123–4." }, { "DOI": "10.1001/jama.2020.12839.e4", "doi-asserted-by": "publisher", "key": "2021040207250726000_2021.03.28.21254507v1.4" }, { "DOI": "10.12688/f1000research.22211.2", "article-title": "Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China", "doi-asserted-by": "crossref", "first-page": "72", "journal-title": "F1000Res", "key": "2021040207250726000_2021.03.28.21254507v1.5", "volume": "9", "year": "2020" }, { "DOI": "10.1056/NEJMoa2007764", "doi-asserted-by": "publisher", "key": "2021040207250726000_2021.03.28.21254507v1.6" }, { "DOI": "10.1016/j.jinf.2020.06.055", "doi-asserted-by": "publisher", "key": "2021040207250726000_2021.03.28.21254507v1.7" }, { "key": "2021040207250726000_2021.03.28.21254507v1.8", "unstructured": "Kalil AC , Patterson TF , Mehta AK , et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2020; EJMoa2031994." }, { "DOI": "10.1093/cid/ciq106", "doi-asserted-by": "publisher", "key": "2021040207250726000_2021.03.28.21254507v1.9" }, { "DOI": "10.1056/NEJMoa1511812", "doi-asserted-by": "publisher", "key": "2021040207250726000_2021.03.28.21254507v1.10" }, { "DOI": "10.3201/eid2209.151164", "doi-asserted-by": "publisher", "key": "2021040207250726000_2021.03.28.21254507v1.11" }, { "key": "2021040207250726000_2021.03.28.21254507v1.12", "unstructured": "U.S. Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma. January 15 2021. Available at: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma (Accessibility verified January 21, 2021)" }, { "DOI": "10.1093/infdis/jiu396", "doi-asserted-by": "publisher", "key": "2021040207250726000_2021.03.28.21254507v1.13" }, { "DOI": "10.1016/j.jinf.2020.04.025", "doi-asserted-by": "publisher", "key": "2021040207250726000_2021.03.28.21254507v1.14" }, { "key": "2021040207250726000_2021.03.28.21254507v1.15", "unstructured": "Gobierno de México. NORMA Oficial Mexicana NOM-253-SSA1-2012, Para la disposición de sangre humana y sus componentes con fines terapéuticos. November 25, 2016. Available at: https://www.cndh.org.mx/sites/default/files/doc/Programas/VIH/LeyesNormasReglamentos/NormaOficialMexicana/NOM-253-SSA1-2012_SangreHumana.pdf (Accessibility verified January 21, 2021)" }, { "DOI": "10.1164/rccm.201908-1581ST", "doi-asserted-by": "publisher", "key": "2021040207250726000_2021.03.28.21254507v1.16" }, { "DOI": "10.1111/jth.14860", "article-title": "ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A comment", "doi-asserted-by": "crossref", "first-page": "2060", "journal-title": "J Thromb Haemost", "key": "2021040207250726000_2021.03.28.21254507v1.17", "volume": "18", "year": "2020" }, { "DOI": "10.1055/s-0040-1710019", "article-title": "Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. T", "doi-asserted-by": "crossref", "first-page": "937", "journal-title": "hromb Haemost", "key": "2021040207250726000_2021.03.28.21254507v1.18", "volume": "120", "year": "2020" }, { "DOI": "10.1056/NEJMoa2021436", "doi-asserted-by": "crossref", "key": "2021040207250726000_2021.03.28.21254507v1.19", "unstructured": "RECOVERY Collaborative Group, Horby P , Lim WS , et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020; EJMoa2021436. Doi:10.1056/NEJMoa2021436" }, { "DOI": "10.1001/jama.2020.1004", "doi-asserted-by": "publisher", "key": "2021040207250726000_2021.03.28.21254507v1.20" }, { "DOI": "10.1136/bmj.m3939", "doi-asserted-by": "publisher", "key": "2021040207250726000_2021.03.28.21254507v1.21" }, { "DOI": "10.1056/NEJMoa2031304", "doi-asserted-by": "crossref", "key": "2021040207250726000_2021.03.28.21254507v1.22", "unstructured": "Simonovich VA , Burgos Pratx LD , Scibona P , et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2020; EJMoa2031304. Doi:10.1056/NEJMoa2031304" }, { "DOI": "10.1056/NEJMoa2033700", "doi-asserted-by": "publisher", "key": "2021040207250726000_2021.03.28.21254507v1.23" }, { "DOI": "10.1186/s12879-020-05507-4", "doi-asserted-by": "publisher", "key": "2021040207250726000_2021.03.28.21254507v1.24" }, { "DOI": "10.1016/j.intimp.2020.107205", "article-title": "Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial", "doi-asserted-by": "crossref", "first-page": "107205", "journal-title": "Int Immunopharmacol", "key": "2021040207250726000_2021.03.28.21254507v1.25", "volume": "90", "year": "2021" } ], "reference-count": 25, "references-count": 25, "relation": {}, "resource": { "primary": { "URL": "http://medrxiv.org/lookup/doi/10.1101/2021.03.28.21254507" } }, "score": 1, "short-title": [], "source": "Crossref", "subtitle": [], "subtype": "preprint", "title": "Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial", "type": "posted-content" }